An Open-Label, Randomized, Controlled, Crossover Study to Assess Nicotine Pharmacokinetics and Subjective Effects of the JUUL System with Three Nicotine Concentrations Relative to Combustible Cigarettes in Adult Smokers
- PMID: 33486526
- PMCID: PMC8628869
- DOI: 10.1093/ntr/ntab001
An Open-Label, Randomized, Controlled, Crossover Study to Assess Nicotine Pharmacokinetics and Subjective Effects of the JUUL System with Three Nicotine Concentrations Relative to Combustible Cigarettes in Adult Smokers
Abstract
Introduction: This randomized, open-label, crossover clinical study evaluated nicotine pharmacokinetics (PK) and subjective effects of the JUUL System (JS; Juul Labs, Inc.) with three nicotine concentrations compared to the usual brand (UB) cigarettes in 24 adult smokers.
Methods: At five study visits, subjects used either the JS in 59 mg/mL, JS 18 mg/mL (two visits), and JS 9 mg/mL (all tobacco-flavored) or smoked their UB cigarette first during a controlled puffing sequence (CPS) and then ad libitum (5 min) use sessions. Blood samples were taken at specified timepoints for 60 min in each session. The modified Product Evaluation Scale assessed subjective effects 30-min post-use in the CPS session.
Results: Maximum plasma nicotine concentration (Cmax-BL), total nicotine exposure (AUC0-60-BL), and rate of plasma nicotine rise were significantly lower for all JS products compared to subjects' UB cigarette in CPS and ad libitum use sessions. In both use sessions these PK parameters were significantly higher for JS 59 mg/mL compared to 18 and 9 mg/mL. Subjective measures of cigarette craving relief and "Enough Nicotine" for JS 59 mg/mL did not differ significantly from UB cigarettes, but JS 18 and 9 mg/mL were rated significantly lower than JS 59 mg/mL and UB cigarettes.
Conclusions: Nicotine exposure and subjective relief were directly related to JS nicotine concentration: higher nicotine concentrations gave rise to significantly greater plasma nicotine levels and relief from craving. Heavier and more dependent smokers may require the greater nicotine delivery of JS 59 mg/mL to successfully transition away from cigarettes.
Implications: It has been suggested that electronic nicotine delivery systems (ENDS) and other alternative nicotine delivery products that more closely mimic the nicotine pharmacokinetics (PK) of cigarettes may facilitate smokers transitioning away from cigarettes. We examined nicotine PK and subjective effects of JUUL System (JS) ENDS with three nicotine concentrations (59, 18 and 9 mg/mL) compared to combustible cigarettes. Nicotine delivery from JS ENDS was nicotine concentration dependent, with higher nicotine concentrations giving rise to higher nicotine exposure. These findings suggest that heavier and more dependent smokers may require ENDS with nicotine concentrations greater than 20 mg/mL to successfully transition away from cigarettes.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.
Figures
Similar articles
-
Abuse liability assessment of the JUUL system in two nicotine concentrations compared to combustible cigarette, nicotine gum and comparator electronic nicotine delivery system.Drug Alcohol Depend. 2020 Dec 1;217:108441. doi: 10.1016/j.drugalcdep.2020.108441. Epub 2020 Nov 24. Drug Alcohol Depend. 2020. PMID: 33250386
-
Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers.Drug Alcohol Depend. 2020 Dec 1;217:108395. doi: 10.1016/j.drugalcdep.2020.108395. Epub 2020 Nov 4. Drug Alcohol Depend. 2020. PMID: 33176942
-
A randomised, crossover, clinical study to assess nicotine pharmacokinetics and subjective effects of the BIDI® stick ENDS compared with combustible cigarettes and a comparator ENDS in adult smokers.Harm Reduct J. 2022 Jun 2;19(1):57. doi: 10.1186/s12954-022-00638-0. Harm Reduct J. 2022. PMID: 35655314 Free PMC article. Clinical Trial.
-
Nicotine delivery and cigarette equivalents from vaping a JUULpod.Tob Control. 2022 Aug;31(e1):e88-e93. doi: 10.1136/tobaccocontrol-2020-056367. Epub 2021 Mar 24. Tob Control. 2022. PMID: 33762429 Free PMC article. Review.
-
Assessing Nicotine Pharmacokinetics of New-Generation Tobacco Products and Conventional Cigarettes: A Systematic Review and Meta-analysis.Nicotine Tob Res. 2025 Apr 22;27(5):783-793. doi: 10.1093/ntr/ntae199. Nicotine Tob Res. 2025. PMID: 39162577
Cited by
-
In vitro toxicological evaluation of aerosols generated by a 4th generation vaping device using nicotine salts in an air-liquid interface system.Respir Res. 2024 Feb 5;25(1):75. doi: 10.1186/s12931-024-02697-2. Respir Res. 2024. PMID: 38317149 Free PMC article.
-
Consumption of JUUL vs. Other E-Cigarette Brands among U.S. E-Cigarette Users: Evidence from Wave 5 of the PATH Study.Int J Environ Res Public Health. 2022 Aug 31;19(17):10837. doi: 10.3390/ijerph191710837. Int J Environ Res Public Health. 2022. PMID: 36078551 Free PMC article.
-
Understanding the nicotine dose delivered by electronic nicotine delivery systems in a single puff: the importance of nicotine flux and puff duration.Tob Control. 2024 Jun 19:tc-2023-058485. doi: 10.1136/tc-2023-058485. Online ahead of print. Tob Control. 2024. PMID: 38897725
-
Part one: abuse liability of Vuse Solo (G2) electronic nicotine delivery system relative to combustible cigarettes and nicotine gum.Sci Rep. 2022 Dec 21;12(1):22080. doi: 10.1038/s41598-022-26417-2. Sci Rep. 2022. PMID: 36543869 Free PMC article. Clinical Trial.
-
Effectiveness of e-cigarettes as aids for smoking cessation: evidence from the PATH Study cohort, 2017-2019.Tob Control. 2023 Aug;32(e2):e145-e152. doi: 10.1136/tobaccocontrol-2021-056901. Epub 2022 Feb 7. Tob Control. 2023. PMID: 35131948 Free PMC article.
References
-
- U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress: a Report of the Surgeon General. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
-
- U.S. Department of Health and Human Services Medicine. Publications and Reports of the Surgeon General. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. - PubMed
-
- Gottlieb S, Zeller M. A nicotine-focused framework for public health. N Engl J Med. 2017;377(12):1111–1114. - PubMed
-
- Institute of Medicine National Academies of Sciences. Clearing the Smoke - Assessing the Science Base for Tobacco Harm Reduction. Washington. D.C.: The National Academies Press; 2001. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical